|
|
News Breaks
|
November 12, 2009
|
| 08:05 EDT |  | CPRX |
| theflyonthewall.com: | Catalyst Pharm reports Q3 diluted EPS (9c) vs. consensus of (11c) | | As a development stage biopharmaceutical company, Catalyst has no revenues to-date. At September 30, 2009, the Company had cash and cash equivalents totaling $4.9M and no long-term debt. :theflyonthewall.com |
|
|
News For CPRX From The Last 14 Days Check below for free stories on CPRX the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 09:08 EDT |  | CPRX |
|
|
February 9, 2012
|
| 08:24 EDT | | CPRX |
|
|
|
|
|
Subscribe for More Information